에 대한 최신 뉴스 Insmed (NASDAQ:INSM) 주식

Insmed

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Exclusives

Trading Ideas

INSM

ISRG

매주, ‘벤징가의 스톡 위스퍼 지수(Benzinga&#39;s Stock Whisper Index)&#39;는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 표면 바로 아래에서 주목을 받을 만한 주식 5종목을 소개한다. 투자자들은 가치가 저평가된, 관심이 적은, 새로운 주식들을 항상 찾고 있다. 소매 거래자들이 사용할 수 있는 방법은 무수히 많기 때문에 새로운 기회를 발견하고 특정 주식이 관심을 가져야 하는 이유를 이해하기 위해 풍부한 정보를 조사하는 것이 어려운 경우가 많다.

벤징가의 &#39;스톡 위스퍼&#39; 지수: 인스메드, 인튜이티브 서지컬, 뮬러 인더스트리즈 및 2종목

Equities

Large Cap

News

Movers

BIDU

NYCB

RIVN

SIRI

Sony Group Corporation American Depositary Shares

SONY

EMPH

이들 11개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 리비안 오토모티브(NASDAQ:RIVN)의 주식은 최근 CPI 데이터에 지난주 21.37% 상승했다. 또한 미국 에너지부(Department of Energy)는 폐쇄되었거나 위험에 처한 11개 자동차 시설을 전기 자동차 제조 공장 및 공급망 허브로 전환하기 위해 17억 달러 투자를 공개했다. 

리비안과 바이두는 지난주 최고 성과를 보인 11개의 대형주 주식 중 일부 (7월 7일-7월 13일)

Tech

COIN

CVNA

MSTR

NVDA

SMCI

엔비디아(NASDAQ:NVDA)는 주식 시장에서 가장 주목할만한 성공 사례 중 하나임이 분명하다. 이 회사는 그래픽 칩과 인공 지능 기술에 대한 전략적 투자에 힘입어 1999년 기업공개 이후 591,078%라는 놀라운 수익률을 기록하며 기술 세계의 정상에 올랐다. 이 주가는 지난 1년간 217.58%, 연초 대비 173.78% 급등했다.

지난 1년 동안 엔비디아를 능가한 8개의 대형주 주식

Insmed Inc

INSMED ORD

Each week,&nbsp;Benzinga&#8217;s Stock Whisper Index&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Read Also:&nbsp;<a href="https://www.benzinga.com/top-stories/24/11/41718416/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-october-2024-where-do-tesla-nvidia-apple-d" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?</a>
Here's a look at the Benzinga Stock Whisper Index for the week of Nov. 8:
Insmed Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>): The biopharmaceutical company saw increased interest from investors over the week, which comes after the company <a href="https://investor.insmed.com/2024-10-31-Insmed-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Business-Update">reported </a>third-quarter financial results and provided a company update in late October. The company said ARIKAYCE had revenue of $93.4 million in the quarter, up 18% year-over-year. 
Insmed also said its NDA submission for Brensocatib in Bronchiectasis is on track for the fourth quarter and is expected to launch in the U.S. in mid-2025. 
H.C. Wainwright reiterated a Buy rating and $90 price target on the stock <a href="https://www.benzinga.com/quote/INSM/analyst-ratings">after the quarterly results</a>. Truist reiterated a Buy rating and raised the price target from $100 to $105. Investor interest could increase in the coming weeks with the company scheduled to participate in several conferences including ones from Guggenheim (Nov. 11), UBS Global (Nov. 12), Wolfe Research (Nov. 20) and Jefferies (Nov. 21).
Insmed shares were up over 8% in the last five trading days, as seen on the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1">Benzinga Pro chart</a> below, and are up over 140% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="506" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135456/Screenshot-234.png" alt="" class="wp-image-638350" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135456/Screenshot-234.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135456/Screenshot-234-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135456/Screenshot-234-768x389.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Applied Industrial Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>): The industrial company was one of several in the sector to see strong interest from readers, which could be related to Donald Trump winning<a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election"> the 2024 election.</a> Industrials were a top performing sector under <a href="https://www.benzinga.com/general/politics/24/11/41783357/how-did-s-p-500-sectors-perform-during-trumps-first-term-could-this-time-be-different">Trump&#8217;s previous four years</a> in the White House. 
The company also recently <a href="https://ir.applied.com/news/news-details/2024/Applied-Industrial-Technologies-Reports-Fiscal-2025-First-Quarter-Results/default.aspx">reported </a>first-quarter financial results with earnings per share of $2.36 and revenue of $1.10 billion, beating Street consensus estimates of $2.27 and $1.09 billion respectively. Applied Industrial also increased its fiscal 2025 earnings per share guidance to a range of $9.25 to $10.00, up from prior guidance of $9.20 to $9.95 and ahead of a Street estimate of $9.39. 
Analysts <a href="https://www.benzinga.com/quote/AIT/analyst-ratings">raised their price targets</a> on the stock after the quarterly results. The stock was up over 15% in the last five trading days and is up over 50% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="503" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135510/Screenshot-236.png" alt="" class="wp-image-638351" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135510/Screenshot-236.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135510/Screenshot-236-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135510/Screenshot-236-768x388.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Sprouts Farmers Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>): The specialty grocery retailer saw strong interest from Benzinga readers during the week, which comes after <a href="https://investors.sprouts.com/news/news-details/2024/Sprouts-Farmers-Market-Inc.-Reports-Third-Quarter-2024-Results/default.aspx">recent </a>quarterly results and with shares trading at 52-week highs. The company's third-quarter earnings per share of 91 cents and revenue of $1.90 billion beat Street estimates of 76 cents per share and $1.88 billion respectively.
The company said the third quarter was exceptional and CEO Jack Sinclair highlighted "robust traffic growth." Same store sales were up 8.4% in the third quarter. The company opened nine new stores, ending the quarter with 428 stores in 23 states. 
Goldman Sachs recently <a href="https://www.benzinga.com/quote/SFM/analyst-ratings">maintained a Buy rating </a>on the stock and raised the price target from $127 to $159. Wells Fargo maintained an Equal-Weight rating on the stock and raised the price target from $90 to $130. 
The stock was up over 10% over the last five trading days, and shares are up over 190% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="503" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135528/Screenshot-237.png" alt="" class="wp-image-638353" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135528/Screenshot-237.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135528/Screenshot-237-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135528/Screenshot-237-768x388.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>): The medical devices company saw strong interest from readers over the last week, with shares trading at 52-week highs Friday. 
The company recently reported <a href="https://www.benzinga.com/news/earnings/24/10/41391471/intuitive-surgical-stock-pops-on-q3-earnings-beat-da-vinci-procedures-climb-18-regulatory-clearance">third-quarter financial results </a>with revenue of $2.04 billion beating a Street consensus estimate of $2.0 billion and earnings per share of $1.84 beating a Street consensus estimate of $1.63. Intuitive Surgical reported revenue growth of 17% year-over-year in the quarter, with worldwide da Vinci procedures up 18% year-over-year. 
The company also placed 379 da Vinci systems in the quarter, up from 312 in the prior quarter. There are 9,539 installed da Vinci surgical systems as of the end of the quarter. Intuitive obtained regulatory clearance for the da Vinci 5 surgical system in South Korea in October. 
The earnings report saw several<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41406234/intuitive-surgical-posts-q3-earnings-beat-these-analysts-raise-forecasts-on-dv5-upt"> analysts raise their price targets </a>on the stock. Analysts see the company's updated da Vinci 5 system, which can be used for more types of surgeries as a growth catalyst moving forward. Shares of Intuitive Surgical were up around six percent in the last five days and are up over 60% year-to-date.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="997" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135542/Screenshot-238.png" alt="" class="wp-image-638354" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135542/Screenshot-238.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135542/Screenshot-238-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135542/Screenshot-238-768x387.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
Mueller Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLI#NYSE">MLI</a>): The industrials company was another in the sector that saw increased interest and a soaring stock price, potential from Trump's 2024 election win. The company recently <a href="https://ir.muellerindustries.com/news/press-releases/detail/178/mueller-industries-inc-reports-third-quarter-2024-earnings">reported </a>third-quarter net sales of $997.8 million, beating a Street consensus estimate of $936.0 million and quarterly earnings per share of $1.48, which beat a Street estimate of $1.32. Mueller Industries said the revenue growth came from recently acquired businesses and higher copper prices in the quarter.
"We anticipated that declining interest rates and moderating inflation, combined with the resolution of election related uncertainty, will create a more stable and favorable environment for us," Mueller CEO Greg Christopher said.
The stock was up 13% over the last five days and is up over 100% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="508" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135559/Screenshot-240.png" alt="" class="wp-image-638355" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135559/Screenshot-240.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135559/Screenshot-240-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135559/Screenshot-240-768x392.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Stay tuned for next week&#8217;s report, and follow Benzinga Pro for all the latest headlines and&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul>
<li><a href="https://www.benzinga.com/exclusives/24/10/41405659/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">October 18</a></li>
<li><a href="https://www.benzinga.com/real-estate/reit/24/10/41549488/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">October 25</a></li>
<li><a href="https://www.benzinga.com/exclusives/24/11/41693907/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">November 1</a></li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/24/11/41779731/trump-victory-sends-bank-stocks-higher-leading-s-p-500-on-regulatory-hopes">Trump Victory Sends Bank Stocks Higher, Leading S&amp;P 500 On Regulatory Hopes</a></li>
</ul>
Photo: Benzinga

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Truist Securities analyst Nicole Germino reiterates Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $100 to $105.

Price Target

Reiteration

Analyst Ratings

Truist Securities Reiterates Buy on Insmed, Raises Price Target to $105

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and maintains $90 price target.

HC Wainwright & Co. Reiterates Buy on Insmed, Maintains $90 Price Target

Biotech

Earnings

Guidance

Health Care

General

Insmed Reiterates Its Guidance For Full-year 2024 Global Arikayce Revenues Of $340M-$360M

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) reported quarterly losses of $(1.27) per share which missed the analyst consensus estimate of $(1.21) by 4.96 percent. The company reported quarterly sales of $93.42 million which beat the analyst consensus estimate of $93.01 million by 0.44 percent. This is a 18.15 percent increase over sales of $79.07 million the same period last year.

Insmed Q3 2024 GAAP EPS $(1.27) Misses $(1.21) Estimate, Sales $93.42M Beat $93.01M Estimate

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) is gearing up to announce its quarterly earnings on Thursday, 2024-10-31. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Insmed will report an earnings per share (EPS) of $-1.21.
Investors in Insmed are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings History Snapshot</h3>
Last quarter the company missed EPS by $0.67, which was followed by a 3.02% increase in the share price the next day.
Here's a look at Insmed's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.27</td>
<td>-1.23</td>
<td>-1.15</td>
<td>-1.12</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.94</td>
<td>-1.06</td>
<td>-1.28</td>
<td>-1.11</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-2.0%</td>
<td>0.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730297050_0.png" alt="eps graph" />
<a href="https://www.benzinga.com/quote/INSM/earnings">To track all earnings releases for Insmed visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse of Insmed's Earnings Potential

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 6.11% on an annualized basis producing an average annual return of 17.42%. Currently, Insmed has a market capitalization of $12.29 billion. 
Buying $1000 In INSM: If an investor had bought $1000 of INSM stock 10 years ago, it would be worth $4,953.54 today based on a price of $71.52 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729874375_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Insmed 10 Years Ago Would Be Worth Today

Insmed's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NYSE">INSM</a>) short percent of float has risen 8.04% since its last report. The company recently reported that it has 13.20 million shares sold short, which is 7.79% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.52 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Insmed Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729786627_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Insmed has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Insmed's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Insmed's peer group average for short interest as a percentage of float is 5.08%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Insmed's Recent Short Interest

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 6.97% on an annualized basis producing an average annual return of 18.54%. Currently, Insmed has a market capitalization of $12.83 billion. 
Buying $100 In INSM: If an investor had bought $100 of INSM stock 10 years ago, it would be worth $552.22 today based on a price of $74.66 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729026018_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today

Truist Securities analyst Nicole Germino maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $85 to $100.

Truist Securities Maintains Buy on Insmed, Raises Price Target to $100

B of A Securities analyst Jason Zemansky maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $84 to $86.

B of A Securities Maintains Buy on Insmed, Raises Price Target to $86

—Data Presented at the CHEST 2024 Annual Meeting—
BRIDGEWATER, N.J., Oct. 8, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today presented positive late-breaking subgroup data from the Phase 3 ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. Posters with the details from these subgroup analyses can be found <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4272617-1&amp;h=1623866854&amp;u=https%3A%2F%2Finvestor.insmed.com%2Fevents%3Fitem%3D127&amp;a=HERE">HERE</a>. These data were presented at the CHEST 2024 Annual Meeting, held October 6-9 in Boston, along with several other presentations from across Insmed's respiratory portfolio.

Insmed Inc Presents New Subgroup Analyses From Landmark Phase 3 ASPEN Study Of Brensocatib In Patients With Bronchiectasis Demonstrate Consistency With Overall Trial Population Results At The CHEST 2024 Annual Meeting

JP Morgan analyst Jessica Fye maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Overweight and raises the price target from $72 to $74.

JP Morgan Maintains Overweight on Insmed, Raises Price Target to $74

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 7.39% on an annualized basis producing an average annual return of 18.6%. Currently, Insmed has a market capitalization of $12.71 billion. 
Buying $100 In INSM: If an investor had bought $100 of INSM stock 10 years ago, it would be worth $561.05 today based on a price of $73.95 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726851688_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Insmed Stock In The Last 10 Years

Looking for broad exposure to the Small Cap Value segment of the US equity market? You should consider the JPMorgan BetaBuilders U.S. Small Cap Equity ETF (ARCA:BBSC), a passively managed exchange traded fund launched on 11/16/2020.
The fund is sponsored by J.P. Morgan. It has amassed assets over $520.35 million, making it one of the average sized ETFs attempting to match the Small Cap Value segment of the US equity market.
<h2>Why Small Cap Value</h2>
Small cap companies have market capitalization below $2 billion. They usually have higher potential than large and mid cap companies with stocks but higher risk.
While value stocks have lower than average price-to-earnings and price-to-book ratios, they also have lower than average sales and earnings growth rates. Value stocks have outperformed growth stocks in nearly all markets when you consider long-term performance, growth stocks are more likely to outpace value stocks in strong bull markets.
<h2>Costs</h2>
Since cheaper funds tend to produce better results than more expensive funds, assuming all other factors remain equal, it is important for investors to pay attention to an ETF&#39;s expense ratio.
Annual operating expenses for this ETF are 0.09%, making it one of the least expensive products in the space.
It has a 12-month trailing dividend yield of 1.48%.
<h2>Sector Exposure and Top Holdings</h2>
Even though ETFs offer diversified exposure which minimizes single stock risk, it is still important to look into a fund&#39;s holdings before investing. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis.
This ETF has heaviest allocation to the Financials sector--about 19.90% of the portfolio. Healthcare and Industrials round out the top three.
Looking at individual holdings, Jpmorgan Us Govt Mmkt Fun accounts for about 1.50% of total assets, followed by Insmed Inc Common Stock (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/insm#NASDAQ">INSM</a>) and Carpenter Technology (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/crs#NYSE">CRS</a>).
The top 10 holdings account for about 5.66% of total assets under management.
<h2>Performance and Risk</h2>
BBSC seeks to match the performance of the MORNINGSTAR US SML CP TRG MRK EXP EXT ID before fees and expenses. The Morningstar US Small Cap Target Market Exposure Extended Index is a free-float adjusted, market-cap weighted index that targets small cap securities traded in the U.S.
The ETF has gained about 7.42% so far this year and it&#39;s up approximately 20.46% in the last one year (as of 09/16/2024). In the past 52-week period, it has traded between $48.58 and $67.50.
The ETF has a beta of 1.08 and standard deviation of 23.45% for the trailing three-year period. With about 796 holdings, it effectively diversifies company-specific risk.
<h2>Alternatives</h2>
JPMorgan BetaBuilders U.S. Small Cap Equity ETF holds a Zacks ETF Rank of 2 (Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors. Because of this, BBSC is an excellent option for investors seeking exposure to the Style Box - Small Cap Value segment of the market. There are other additional ETFs in the space that investors could consider as well.
The Avantis U.S. Small Cap Value ETF (ARCA:AVUV) and the Vanguard Small-Cap Value ETF (ARCA:VBR) track a similar index. While Avantis U.S. Small Cap Value ETF has $12.95 billion in assets, Vanguard Small-Cap Value ETF has $29.58 billion. AVUV has an expense ratio of 0.25% and VBR charges 0.07%.
<h2>Bottom-Line</h2>
Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors.
<a href="https://www.zacks.com/stock/news/2336240/should-jpmorgan-betabuilders-u-s-small-cap-equity-etf-bbsc-be-on-your-investing-radar?cid=CS-BENZ-FT-style_box_etf-2336240">To read this article on Zacks.com click here.</a>

Mid Cap

Sector ETFs

Dividends

Small Cap

Markets

ETFs

AVUV

BBSC

Should JPMorgan BetaBuilders U.S. Small Cap Equity ETF Be on Your Investing Radar?

Insmed's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NYSE">INSM</a>) short percent of float has fallen 9.3% since its last report. The company recently reported that it has 12.23 million shares sold short, which is 7.22% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.84 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Insmed Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726502419_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Insmed has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Insmed's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Insmed's peer group average for short interest as a percentage of float is 6.00%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(INSM) - Analyzing Insmed's Short Interest

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 7.82% on an annualized basis producing an average annual return of 18.36%. Currently, Insmed has a market capitalization of $12.29 billion. 
Buying $1000 In INSM: If an investor had bought $1000 of INSM stock 10 years ago, it would be worth $5,347.05 today based on a price of $71.49 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725984016_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cantor Fitzgerald analyst Josh Schimmer reiterates Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Overweight.

Cantor Fitzgerald Reiterates Overweight on Insmed

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 7.94% on an annualized basis producing an average annual return of 18.82%. Currently, Insmed has a market capitalization of $13.31 billion. 
Buying $1000 In INSM: If an investor had bought $1000 of INSM stock 10 years ago, it would be worth $5,609.70 today based on a price of $77.45 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724680820_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Insmed 10 Years Ago Would Be Worth This Much Today

Here's the major earnings before the open tomorrow

Insmed GAAP EPS of -$1.27 misses by $0.06, revenue of $93.43M beats by $0.26M

Insmed Incorporated (INSM) Q3 2024 Earnings Call Transcript

Ritu Baral, an analyst from TD Cowen, maintained the Buy rating on Insmed (INSM – Research Report). The associated price target remains the same wi...

Insmed's Strong Revenue Growth and Promising Pipeline Drive Buy Rating

In a report released today, Leon Wang from Barclays maintained a Buy rating on Insmed (INSM – Research Report), with a price target of $90.00. The ...

Barclays Sticks to Its Buy Rating for Insmed (INSM)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY – Research Report) and Insmed (INSM – Resear...

Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY) and Insmed (INSM)

In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Insmed (INSM – Research Report), with a price target of $75.00...

Evercore ISI Reaffirms Their Buy Rating on Insmed (INSM)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Haleon PLC Sponsored ADR (HLN – Research Report), Insmed (INSM – ...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Haleon PLC Sponsored ADR (HLN), Insmed (INSM) and Galapagos (GLPG)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Argenx Se (ARGX – Research Report), Regeneron (REGN ...

Analysts Are Bullish on These Healthcare Stocks: Argenx Se (ARGX), Regeneron (REGN)

Truist Financial analyst Nicole Germino maintained a Buy rating on Insmed (INSM – Research Report) yesterday and set a price target of $105.00. The...

Truist Financial Reaffirms Their Buy Rating on Insmed (INSM)

ABEV

AGIO

ALGM

ALNY

AMKBY

APTV

ARGX

ATGFF

AVNT

BALL

BAND

BBVA

BNPQF

CCRD

CIFR

CMCSA

CMPS

CPSH

DFIN

DINO

FLWS

FNMA

GLPG

GNRC

GPRE

IDCC

IDXX

ISNPY

ITRI

REGN

Press Releases

Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results

Insmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024

Insmed Unites Across Communities Around the World During Third Annual Global Day of Good

Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List

Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update

Insmed To Present at November 2024 Investor Conferences

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BeiGene, Ltd. - American Depositary Shares

BeiGene

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Truist Securities

HC Wainwright & Co.

B of A Securities

JP Morgan

TD Cowen

매주, ‘벤징가의 스톡 위스퍼 지수(Benzinga's Stock Whisper Index)'는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 <a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">표면 바로 아래에서 주목</a>을 받을 만한 주식 5종목을 소개한다.
투자자들은 가치가 저평가된, 관심이 적은, 새로운 주식들을 항상 찾고 있다. 소매 거래자들이 사용할 수 있는 방법은 무수히 많기 때문에 새로운 기회를 발견하고 특정 주식이 관심을 가져야 하는 이유를 이해하기 위해 풍부한 정보를 조사하는 것이 어려운 경우가 많다.
다음은 11월 8일 주간 벤징가 ‘스톡 위스퍼' 지수의 개요:
인스메드 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>):
이 생명공학 회사는 10월 말에 3분기 재무 결과와 사업 업데이트를 <a href="https://investor.insmed.com/2024-10-31-Insmed-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Business-Update" target="_blank" rel="noopener">발표</a>한 후 투자자들의 관심이 증가하고 있다. 이 회사는 아리케이스(ARIKAYCE)의 매출이 3분기에 9,340만 달러로 전년 대비 18% 증가했다고 밝혔다.
인스메드는 또한 기관지 확장증 치료제 브렌소카팁(Brensocatib)에 대한 NDA 제출이 4분기에 예정되어 있으며, 2025년 중반에 미국에서 출시될 것으로 예상된다고 밝혔다.
H.C. 웨인라이트는 분기 실적 발표 후 주식에 대해 매수 등급과 90달러의 목표 주가를 재확인했다. 트루이스트(Truist)는 매수 등급을 재확인하고 목표 주가를 100달러에서 105달러로 상향 조정했다. 이 회사는 11월 11일에 구겐하임(Guggenheim), 11월 12일 UBS 글로벌, 11월 20일 울프 리서치(Wolfe Research) 및 11월 21일 제프리스(Jefferies)를 포함한 여러 컨퍼런스에 참여할 예정이어서 앞으로 몇 주 안에 투자자들의 관심이 증가할 수 있다.
인스메드 주식은 최근 5일 거래일 동안 9% 이상 상승했으며, 2024년 연초 대비 145% 이상 상승했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135456/Screenshot-234.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
어플라이드 인더스트리얼 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>):
이 산업 회사는 도널드 트럼프가 <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election" target="_blank" rel="noopener">2024년 선거</a>에서 승리하는 것과 관련이 있을 수 있는 독자들의 강한 관심을 본 분야의 여러 회사 중 하나였다. 산업 섹터는 트럼프 대통령의 백악관 <a href="https://www.benzinga.com/general/politics/24/11/41783357/how-did-s-p-500-sectors-perform-during-trumps-first-term-could-this-time-be-different" target="_blank" rel="noopener">재임 4년 동안</a> 최고 실적을 거둔 부문이었다.
또한 이 회사는 최근 1분기 재무 결과를 <a href="https://ir.applied.com/news/news-details/2024/Applied-Industrial-Technologies-Reports-Fiscal-2025-First-Quarter-Results/default.aspx" target="_blank" rel="noopener">발표</a>하여 주당 순이익이 2.36달러 그리고 매출이 11억 달러로, 스트리트 컨센서스 추정치인 22억 7천만 달러와 10억 9천만 달러를 각각 넘어섰다. 어플라이드 인더스트리얼은 또한 2025 회계연도 주당 이익 지침을 이전 지침인 9.20~9.95달러에서 9.25~10.00달러 범위로 상향 조정했다. 이는 월가의 추정치인 9.39달러보다 앞선 것이다.
이 분기 실적 발표 후 애널리스트들은 <a href="https://www.benzinga.com/quote/AIT/analyst-ratings" target="_blank" rel="noopener">목표 주가를 상향</a> 조정했다. 주식은 최근 5일 거래일 동안 16% 이상 상승했으며, 2024년 연초 대비 57% 이상 상승했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135510/Screenshot-236.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
스프라우츠 파머스 마켓 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>):
이 전문 식료품 소매업체는 벤징가 독자들 사이에서 강한 관심을 받았으며, 이는 <a href="https://investors.sprouts.com/news/news-details/2024/Sprouts-Farmers-Market-Inc.-Reports-Third-Quarter-2024-Results/default.aspx" target="_blank" rel="noopener">최근</a> 분기 실적 발표 후 주가가 52주 최고가로 거래되고 있는 것과 관련이 있다. 이 회사의 3분기 주당 순이익은 91센트와 매출 19억 달러로 스트리트 예상치인 주당 76센트와 18억 8천만 달러를 각각 웃돌았다.
이 회사는 3분기가 예외적이었다고 언급했으며, CEO 잭 싱클레어(Jack Sinclair)는 &#8220;견고한 방문객 성장&#8221;을 강조했다. 동일 매장 매출이 3분기 동안 8.4% 증가했다. 이 회사는 9개의 새로운 매장을 열어 23개 주에 428개의 매장을 운영하고 있다.
골드만삭스는 최근 주식에 대해 <a href="https://www.benzinga.com/quote/SFM/analyst-ratings" target="_blank" rel="noopener">매수 등급을 유지</a>하고 목표 주가를 127달러에서 159달러로 상향 조정했다. 웰스 파고는 주식에 대해 중립 등급을 유지하고 목표 주가를 90달러에서 130달러로 상향 조정했다.
주식은 최근 5일 거래일 동안 11% 이상 상승했으며, 2024년 연초 대비 195% 이상 상승했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135528/Screenshot-237.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
인튜이티브 서지컬 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>):
이 의료 기기 회사는 지난주 독자들 사이에서 강한 관심을 받았으며, 주가가 금요일에 52주 최고가로 거래되고 있다.
이 회사는 최근 <a href="https://kr.benzinga.com/news/usa/stocks/%EC%9D%B8%ED%8A%9C%EC%9D%B4%ED%8B%B0%EB%B8%8C-%EC%84%9C%EC%A7%80%EC%BB%AC%EC%9D%98-%EC%A3%BC%EC%8B%9D%EC%9D%80-%EA%B0%95%EB%A0%A5%ED%95%9C-3%EB%B6%84%EA%B8%B0-%EC%8B%A4%EC%A0%81%EC%97%90-%EC%8B%9C/" target="_blank" rel="noopener">3분기 재무 결과</a>를 발표했으며, 매출이 20억 4천만 달러로 컨센서스 예상치인 20억 달러를 초과했고, 주당 순이익이 1.84달러로 컨센서스 예상치인 1.63달러를 초과했다. 인튜이티브 서지컬은 3분기 동안 전년 대비 17%의 매출 성장을 보고했으며, 전 세계 다 빈치(da Vinci) 수술 건수가 전년 대비 18% 증가했다.
이 회사는 3분기 동안 379개의 다 빈치 시스템을 설치했으며, 이는 이전 분기의 312개에서 증가한 수치이다. 3분기 말 기준으로 설치된 다 빈치 수술 시스템은 9,539개이다. 인튜이티브는 10월에 한국에서 다 빈치 5 수술 시스템에 대한 규제 승인을 받았다.
이 실적 발표 이후 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41406234/intuitive-surgical-posts-q3-earnings-beat-these-analysts-raise-forecasts-on-dv5-upt" target="_blank" rel="noopener" data-google-interstitial="false">여러 애널리스트들이 목표 주가를 상향</a> 조정했다. 애널리스트들은 회사의 최신 다 빈치 5 시스템이 더 많은 종류의 수술에 사용할 수 있어 성장 촉매제로 작용할 것으로 보고 있다. 인튜이티브 서지컬 주식은 최근 5일 거래일 동안 6.02% 상승했으며, 2024년 연초 대비 62.08% 상승했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135542/Screenshot-238.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
뮬러 인더스트리즈 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLI#NYSE">MLI</a>):
이 산업 회사는 트럼프의 2024년 대선 승리 가능성과 관련하여 증가한 관심과 주가 상승을 경험했다. 이 회사는 최근 3분기 순매출이 9억 9,780만 달러로 컨센서스 예상치인 9억 3,600만 달러를 초과했으며, 분기 주당 순이익이 1.48달러로 예상치인 1.32달러를 초과했다고 <a href="https://ir.muellerindustries.com/news/press-releases/detail/178/mueller-industries-inc-reports-third-quarter-2024-earnings" target="_blank" rel="noopener">발표</a>했다. 뮬러 인더스트리즈는 최근 인수한 사업과 분기 중 구리 가격 상승이 매출 성장에 기여했다고 밝혔다.
뮬러의 CEO인 그렉 크리스토퍼(Greg Christopher)는 &#8220;우리는 금리 인하와 인플레이션 완화, 선거 관련 불확실성의 해소가 더 안정적이고 유리한 환경을 만들어 줄 것으로 예상했다&#8221;고 말했다.
주식은 최근 5일 동안 15.89% 상승했으며, 2024년 연초 대비 102% 이상 상승했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135559/Screenshot-240.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
다음 주 보고서를 계속 지켜봐 주시기 바랍니다. 여기에서 Benzinga Pro를 팔로우하여 모든 최신 헤드라인과 <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">시장을 움직이는 주요 스토리</a>를 확인하세요.
Photo: Benzinga
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

벤징가의 '스톡 위스퍼' 지수: 인스메드, 인튜이티브 서지컬, 뮬러 인더스트리즈 및 2종목

이들 11개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>리비안 오토모티브(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>)의 주식은 <a href="https://www.benzinga.com/economics/macro-economic-events/24/07/39728268/inflation-slows-more-expected-to-3-in-june-heightens-expectations-for-rate-cuts-t" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">최근 CPI 데이터</a>에 지난주 21.37% 상승했다. 또한 미국 에너지부(Department of Energy)는 폐쇄되었거나 위험에 처한 11개 자동차 시설을 전기 자동차 제조 공장 및 공급망 허브로 전환하기 위해 17억 달러 투자를 공개했다.</li>
<li>엔페이즈 에너지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMPH#NASDAQ">EMPH</a>)의 주가는 회사가 태양광 프로젝트가 &#8216;국내 콘텐츠 보너스 크레딧&#8217; 자격을 갖추는 데 도움이 될 수 있는 주거용 및 상업용 제품을 발표한 후 21.15% 상승했다.</li>
<li>D.R. 호튼(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>)의 주가는 12.53% 급등했다. 예상보다 부진한 6월 CPI 수치로 인해 국채 수익률이 하락하면서 주택 건설업체, 건축 회사 및 주택 관련 회사들의 주가는 지난주 상승했다.</li>
<li>탑빌드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>)의 주가는 예상보다 부진한 6월 CPI 수치에 이어 지난주 주택 건설업체, 건축업체, 주택 관련 주가 상승하면서 12.15% 상승했다.</li>
<li>바이두(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>)의 주가는 중국 내 아폴로고(<a href="https://www.benzinga.com//node/39709053" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">Apollo Go</a>) 로보택시 서비스에 대한 관심이 높아지고 있다는 보도에 11.80% 상승했다.</li>
<li>코닝(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>)의 주가는 2분기 핵심 매출 가이던스를 상향 조정한 후 11.54% 상승했습니다. 몇몇 분석가들도 주식 가격 <a href="https://www.benzinga.com/quote/GLW/analyst-ratings" target="_blank" rel="noreferrer noopener">예측</a>을 높였다.</li>
<li>인스메드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>)의 주가는 분석가들이 <a href="https://www.benzinga.com/quote/insm/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">주식 가격 전망</a>을 높이면서 지난주 11.04% 상승했다.</li>
<li>톨 브라더스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>)의 주가는 10.96% 상승했다. 예상보다 부진한 6월 CPI로 인해 국채수익률이 하락하면서 주택 건설업체, 건축업체 및 주택 관련 기업의 주가가 상승했다.</li>
<li>소니 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>)의 주가는 파라마운트 글로벌(Paramount Global)이 스카이댄스 미디어(Skydance Media)와 합병하기로 합의한 이후 10.53% 상승했다.</li>
<li>빈패스트 오토(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>)의 주가는 9.73% 급등했다. 블룸버그는 수요일 이 회사가 <a href="https://www.benzinga.com//node/39739997" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">인도네시아 확장</a>을 위해 2억 5천만 달러의 은행 대출을 모색하고 있다고 보도했다.</li>
<li>킨로스 골드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGC#NYSE">KGC</a>)의 주가는 여러 분석가들이 <a href="https://www.benzinga.com/quote/KGC/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 예측을 상향 조정</a>한 후 지난주에 8.75% 상승했다.</li>
</ol>
다음 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/%eb%84%b7%ed%94%8c%eb%a6%ad%ec%8a%a4%ec%99%80-%eb%8d%b8%ed%83%80-%ed%95%ad%ea%b3%b5%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-10/" target="_blank" rel="noopener">넷플릭스, 델타 항공 및 허브스팟이 지난주 가장 성과가 좋지 못했던 대형주 주식 10개 중 일부 (7월 7일-7월 13일)</a></li>
<li><a href="https://kr.benzinga.com/news/%ec%83%a4%ec%98%a4%ed%8e%91-%eb%b0%8f-%ed%80%80%ed%85%80%ec%8a%a4%ec%bc%80%ec%9d%b4%ed%94%84%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%97%ac/" target="_blank" rel="noopener">샤오펑 및 퀀텀스케이프가 지난주 가장 큰 성과를 보인 중형 주식 11개 중 일부 (7월 7일-7월 13일)</a></li>
</ul>
Photo Courtesy of Rivian Automotive
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)는 <a href="https://www.benzinga.com/news/24/06/39380352/nvidia-to-rally-around-53-here-are-10-top-analyst-forecasts-for-tuesday">주식 시장</a>에서 가장 주목할만한 성공 사례 중 하나임이 분명하다.
이 회사는 그래픽 칩과 인공 지능 기술에 대한 전략적 투자에 힘입어 1999년 기업공개 이후 591,078%라는 놀라운 수익률을 기록하며 <a href="https://www.benzinga.com/tech" target="_blank" rel="noopener" data-google-interstitial="false">기술 세계</a>의 정상에 올랐다. 이 주가는 지난 1년간 217.58%, 연초 대비 173.78% 급등했다.
그러나 지난 1년 동안 몇몇 다른 대형주들은 엔비디아를 능가했다. 그 중 8개는 다음과 같다.
<ol>
<li>마이크로스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) — 비트코인에 대한 대규모 투자로 알려진 마이크로스트레티지는 상당한 가격 변동을 겪었지만 엔비디아의 연간 성과를 앞질렀다.
<ul>
<li>업종: 기술</li>
<li>산업: 소프트웨어 &#8211; 응용 프로그램</li>
<li>시가총액: 260.7억 달러</li>
<li>가격: 1,469.43달러</li>
<li>1년 수익률: 400.85%</li>
<li>올 해 수익률: 132.64%</li>
</ul>
</li>
<li>카바나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) — 카바나의 혁신적인 온라인 자동차 판매 플랫폼은 특히 시장이 팬데믹 이후 반등을 하자 강한 성과를 내고 있다.
<ul>
<li>업종: 소비자 순환</li>
<li>산업: 오토 및 트럭 딜러쉽스</li>
<li>시가총액: 129.6억 달러</li>
<li>1년 수익률: 337.52%</li>
<li>올 해 수익률: 109.26%</li>
</ul>
</li>
<li>코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) — 선도적인 암호화폐 거래소인 코인베이스가 암호화폐 붐에 대한 이점을 살려 엔비디아의 성장을 앞섰다.
<ul>
<li>업종: 금융</li>
<li>산업: 금융 데이터 및 주식 거래소</li>
<li>시가총액: 579.4억 달러</li>
<li>가격: 235.95달러</li>
<li>1년 수익률: 324.45%</li>
<li>올 해 수익률: 35.67%</li>
</ul>
</li>
<li>버티브 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) — 전기 장비 부문에서 버티브의 강한 성과는 탄탄함과 성장을 보여주고 있다.
<ul>
<li>업종: 산업재</li>
<li>산업: 전기 장비 및 부품</li>
<li>시가총액: 356.9억 달러</li>
<li>가격: 95.34달러</li>
<li>1년 수익률: 322.98%</li>
<li>올 해 수익률: 98.50%</li>
</ul>
</li>
<li>슈퍼 마이크로 컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) — 슈퍼 마이크로 컴퓨터는 고성능 컴퓨팅 솔루션에 대한 수요 증가에서 이득을 보았으며 이로 인해 엔비디아의 이익을 능가했다.
<ul>
<li>업종: 기술</li>
<li>산업: 컴퓨터 하드웨어</li>
<li>시가총액: 538.8억 달러</li>
<li>가격: 920.01달러</li>
<li>1년 수익률: 298.67%</li>
<li>올 해 수익률: 223.65%</li>
</ul>
</li>
<li>비스트라(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) — 비스트라는 유틸리티 부문의 강한 성과로, 엔비디아의 성과를 웃돌았다..
<ul>
<li>업종: 유틸리티</li>
<li>산업: 독립형 발전기</li>
<li>시가총액: 304.3억 달러</li>
<li>가격: 87.58달러</li>
<li>1년 수익률: 249.48%</li>
<li>올 해 수익률: 127.36%</li>
</ul>
</li>
<li>앱러빈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) — 앱러빈의 모바일 앱 기술은 근대적인 성장을 추진하였으며, 이로써 기술 부문에서 주요 성과 중 하나가 되었다.
<ul>
<li>업종: 기술</li>
<li>산업: 소프트웨어 &#8211; 응용 프로그램</li>
<li>시가총액: 266억 달러</li>
<li>가격: 80.84달러</li>
<li>1년 수익률: 237.25%</li>
<li>올 해 수익률: 102.86%</li>
</ul>
</li>
<li>인스메드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) — 인스메드의 생명과학 분야의 진보와 강한 시장 성과로 인해 지난 1년간 엔비디아의 이익을 앞질렀다.
<ul>
<li>업종: 헬스케어</li>
<li>산업: 생명과학</li>
<li>시가총액: 105.7억 달러</li>
<li>가격: 65.58달러</li>
<li>1년 수익률: 227.90%</li>
<li>올 해 수익률: 111.62%</li>
</ul>
</li>
</ol>


Image: Shutterstock

Comments

Insmed

뉴스

에 대한 최신 뉴스 Insmed (NASDAQ:INSM) 주식

토요일, 11월 09, 2024

일요일, 7월 14, 2024

수요일, 6월 19, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌